(Q40850127)

24 September 2017

Soluble Fas-ligand (sFasL) in human astrocytoma cyst fluid is cytotoxic to T-cells: another potential means of immune evasion (English)

1 reference

evasion of host immune response

24 September 2017

1 reference

1 reference

Frankel B

1

1 reference

24 September 2017

Longo SL

series ordinal

2

1 reference

24 September 2017

Canute GW

series ordinal

3

1 reference

24 September 2017

1 May 2000

1 reference

Journal of Neuro-Oncology

24 September 2017

1 reference

24 September 2017

48

1 reference

24 September 2017

1

1 reference

24 September 2017

21-26

1 reference

https://scigraph.springernature.com/pub.10.1023/a:1006473800589

24 September 2017

0 references

cites work

Fas Ligand-Induced Apoptosis as a Mechanism of Immune Privilege

1 reference

12 December 2020

Factors, including transforming growth factor beta, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells.

1 reference

12 December 2020

Detectable concentrations of Fas ligand in cerebrospinal fluid after severe head injury.

1 reference

12 December 2020

Activated B cells express functional Fas ligand

1 reference

12 December 2020

Constitutive and induced expression of APO-1, a new member of the nerve growth factor/tumor necrosis factor receptor superfamily, in normal and neoplastic cells.

1 reference

12 December 2020

Lymphocyte apoptosis induced by CD95 (APO-1/Fas) ligand-expressing tumor cells--a mechanism of immune evasion?

1 reference

12 December 2020

Fas ligand expression in glioblastoma cell lines and primary astrocytic brain tumors.

1 reference

12 December 2020

Fas ligand expression by astrocytoma in vivo: maintaining immune privilege in the brain?

1 reference

12 December 2020

Transforming growth factor beta is an important immunomodulatory protein for human B lymphocytes

1 reference

12 December 2020

Transforming growth factor-beta 2 induces apoptosis of murine T cell clones without down-regulating bcl-2 mRNA expression

1 reference

12 December 2020

Hydroxyurea accelerates the loss of epidermal growth factor receptor genes amplified as double-minute chromosomes in human glioblastoma multiforme

1 reference

12 December 2020

Immunotherapy of malignant gliomas

1 reference

12 December 2020

Human glioma-induced immunosuppression involves soluble factor(s) that alters monocyte cytokine profile and surface markers

1 reference

12 December 2020

The Pathogenesis of Cerebral Gliomatous Cysts

1 reference

12 December 2020

Immunohistological study of mononuclear cell infiltrate in malignant gliomas.

1 reference

12 December 2020

Cystic lesions accompanying extra-axial tumours.

1 reference

12 December 2020

Glioblastoma cells release interleukin 1 and factors inhibiting interleukin 2-mediated effects.

1 reference

12 December 2020

The Fas counterattack: cancer as a site of immune privilege

1 reference

12 December 2020

Effects of transforming growth factor beta on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness

1 reference

12 December 2020

Human glioblastoma cells release interleukin 6 in vivo and in vitro

1 reference

12 December 2020

Interleukin-8 is produced in neoplastic and infectious diseases of the human central nervous system.

1 reference

12 December 2020

Metalloproteinase-mediated release of human Fas ligand

1 reference

12 December 2020

Effect of the expression of transforming growth factor-beta 2 in primary human glioblastomas on immunosuppression and loss of immune surveillance

1 reference

12 December 2020

Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family

1 reference

12 December 2020

Immunosuppression and transforming growth factor-beta in glioblastoma. Preferential production of transforming growth factor-beta 2.

1 reference

12 December 2020

Release of preformed Fas ligand in soluble form is the major factor for activation-induced death of Jurkat T cells

1 reference

12 December 2020

Expression of the functional soluble form of human fas ligand in activated lymphocytes.

1 reference

12 December 2020

Fas-mediated cytotoxicity by freshly isolated natural killer cells

1 reference

12 December 2020

Fas ligand and immune evasion

1 reference

12 December 2020

Presence of immunosuppressive factors in brain-tumor cyst fluid.

1 reference

12 December 2020

Transforming growth factor-beta 2 down-regulates HLA-DR antigen expression on human malignant glioma cells.

1 reference

12 December 2020

Quantitative study of monocyte chemoattractant protein-1 (MCP-1) in cerebrospinal fluid and cyst fluid from patients with malignant glioma.

1 reference

12 December 2020

Plasma Fas ligand, an inducer of apoptosis, and plasma soluble Fas, an inhibitor of apoptosis, in patients with chronic congestive heart failure.

1 reference

12 December 2020

Human astrocytomas co-expressing Fas and Fas ligand also produce TGFbeta2 and Bcl-2.

1 reference

12 December 2020

Co-expression of Fas and Fas ligand in malignant glial tumors and cell lines.

1 reference

12 December 2020

Human astrocytoma cells are capable of producing macrophage inflammatory protein-1beta

1 reference

12 December 2020

Soluble Fas (APO-1, CD95) and soluble Fas ligand in rheumatic diseases

1 reference

12 December 2020

Inhibition of cytokine production by cyclosporin A and transforming growth factor beta

1 reference

12 December 2020

Role of Fas ligand (CD95L) in immune escape: the tumor cell strikes back

1 reference

12 December 2020

Production of transforming growth factor beta by human T lymphocytes and its potential role in the regulation of T cell growth

1 reference

12 December 2020

Co-expression of Fas and Fas ligand in human non-astrocytic glial tumors.

1 reference

12 December 2020

Involvement of an ICE-like protease in Fas-mediated apoptosis

1 reference

12 December 2020

Identifiers

DOI

10.1023/A:1006473800589

1 reference

Dimensions Publication ID

24 September 2017

0 references

1 reference